Sangamo Therapeutics Receives "Buy" Rating from HC Wainwright & Co., with Unchanged Target Price of $10.00.

Sangamo Therapeutics (SGMO) has been reiterated with a "Buy" rating by HC Wainwright & Co., with a target price of $10.00. The firm's analysts maintain confidence in the company's potential to meet growth expectations. Based on 5 analysts' one-year price targets, the average target price is $4.10, indicating a 741.89% upside from the current price of $0.49.

Sangamo Therapeutics (SGMO), a clinical-stage genomic medicine company, has seen its stock receive a reiterated "Buy" rating from HC Wainwright & Co. [1] The investment research firm, known for its thorough analysis, has maintained its confidence in the company's potential to meet growth expectations. The firm's analysts have set a target price of $10.00 for the biopharmaceutical company's stock.

The "Buy" rating from HC Wainwright & Co. indicates a stable assessment from previous evaluations, as the firm continues to support the stock without altering its outlook. This reiteration provides investors with reassurance regarding the company's long-term prospects.

Based on the one-year price targets offered by five analysts, the average target price for Sangamo Therapeutics Inc (SGMO) is $4.10, with a high estimate of $10.00 and a low estimate of $1.50. This average target price implies an upside of 741.89% from the current price of $0.49. The consensus recommendation from seven brokerage firms is 2.1, indicating an "Outperform" status.

GuruFocus estimates the fair value for Sangamo Therapeutics Inc (SGMO) to be $0.96 in one year, suggesting a potential upside of 97.13% from the current price of $0.487.

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases. The company's clinical-stage product candidates include ST-920, TX200, SB-525, and BIVV003, each in various stages of clinical trials for conditions like Fabry disease, immune-mediated rejection in kidney transplantation, hemophilia A, and sickle cell disease.

The stock's recent performance has been mixed, with shares trading up $0.06 to reach $0.49 on Tuesday, June 24, 2025. The stock has a market capitalization of $115.19 million, a price-to-earnings ratio of -1.27, and a beta of 1.20. The stock's fifty-day simple moving average is $0.58, and its 200-day simple moving average is $1.00. The stock has a 52-week low of $0.30 and a 52-week high of $3.18.

Several institutional investors have recently bought and sold shares of the company. E Fund Management Co. Ltd., JPMorgan Chase & Co., PNC Financial Services Group Inc., SBI Securities Co. Ltd., and Captrust Financial Advisors have all increased their stakes in Sangamo Therapeutics during the 4th quarter.

In summary, Sangamo Therapeutics (SGMO) maintains a solid position in the market with a "Buy" rating from HC Wainwright & Co. The company's optimistic price targets and analyst recommendations suggest potential upside for investors.

References:
[1] https://www.marketbeat.com/instant-alerts/sangamo-therapeutics-nasdaqsgmo-given-buy-rating-at-hc-wainwright-2025-06-24/
[2] https://www.gurufocus.com/news/2943195/sangamo-therapeutics-sgmo-receives-reiterated-buy-rating-from-hc-wainwright-co-sgmo-stock-news